7% peripheral artery disease at baseline (9.1% polyvascular). The main risk factors were hypertension (76%), hypercholesterolemia (60%), and smoking (52.3%) in patients with established atherothrombosis; and hypertension (89.7%), diabetes (80.8%), and hypercholesterolemia (73.9%) in those with risk factors only. Four-year all-cause mortality steeply increased with none (6.8%), 1 (9.2%), 2 (15.5%), and 3 (29.2%) symptomatic arterial disease locations. In patients with only 1 location, cardiovascular mortality was significantly

higher with peripheral artery disease (11.3%) than with cerebrovascular disease (6%) Etomoxir supplier or coronary artery disease (5.1%). Significant baseline predictors of 4-year all-cause mortality were congestive heart failure (hazard ratio [HR]: 3.81), body mass index <20 (HR: 2.32), hypertension (HR: 1.84), VEGFR inhibitor polyvascular disease (HR: 1.69), and age =65 years (HR: 1.47), whereas statin use (HR: 0.49) and body mass index =30 (HR: 0.58) were associated with a reduced risk. Conclusions: Hypertension was the main modifiable risk factor for atherothrombosis and all-cause mortality in this Latin American cohort. Nearly one-third of the population with

3 symptomatic vascular-disease locations died at 4-year follow-up.

The REACH registry is sponsored by sanofi, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan). The REACH registry is endorsed by the World Heart Federation. The REACH registry enforces a no-ghostwriting policy. This manuscript was written and edited by the authors, who take full responsibility for its content. Dr. Cantu-Brito and Dr. Chiquete wrote the first draft of this manuscript. Dr. Cantu-Brito has received research grants from sanofi, Ferrer Grupo and Bayer, as well as speaker honoraria PD-1/PD-L1 Inhibitor 3 cell line from sanofi. Dr. Chiquete has received research grants from sanofi and Ferrer Grupo, as well as speaker honoraria from Novartis. Dr. Ruiz-Sandoval has received research grants from sanofi, Boehringer Ingelheim, and Ferrer Grupo. Dr. Gaxiola has received research grants from sanofi and Eli Lilly, as well as consultancy and speaker honoraria from Sanofi, Eli Lilly, Pfizer, AstraZeneca, and Abbott. Dr. Albuquerque has received research grants from sanofi, AstraZeneca, Servier, Roche, and BMS/Pfizer, as well as consultancy and speaker honoraria from sanofi and AstraZeneca. Dr. Corbalan has no relevant disclosures. Mrs. Ramos is an employee at sanofi, in the Clinical Research Department. Dr. Deepak L.